

**A Klinikai Laboratóriumi Kutató Tanszék  
publikációs listája  
2009-2016 (112 db cikk, IF: 327.748)**

**2016 (7 db cikk, IF: 23.956)**

1. Muszbek L, Katona É  
Diagnosis and Management of Congenital and Acquired FXIII Deficiencies  
SEMIN THROMB HEMOST. 2016; DOI: 10.1055/s-0036-1572326 IF: 3.876 (2014. évi)
2. Kerényi A, Beke Debreceni I, Oláh Z, Ilonczai P, Bereczky Z, Nagy B, Muszbek L, Kappelmayer J  
Evaluation of flow cytometric HIT assays in relation to an IgG-Specific immunoassay and clinical outcome  
CYTOMETRY PART B – CLINICAL CYTOMETRY 2016; article in press, DOI: 10.1002/cyto.b.21362 IF: 2.398 (2014. évi)
3. Bagoly Z, Homoródi N, Kovács EG, Sarkady F, Csiba L, Édes I, Muszbek L  
How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?  
PLATELETS 2016; 27(1): 59-65 IF: 2.982 (2014. évi)
4. Homoródi N, Kovács EG, Leé S, Katona É, Shemirani AH, Haramura G, Balogh L, Bereczky Z, Szőke G, Péterfy H, Kiss RG, Édes I, Muszbek L  
The lack of aspirin resistance in patients with coronary artery disease  
J TRANSL MED. 2016; 14 (1): 74 DOI: 10.1186/s12967-016-0827-7 IF: 3.930 (2014. évi)
5. Gindele R, Oláh Z, Ilonczai P, Speker M, Udvari Á, Selmeczi A, Pfliegler G, Marján E, Kovács B, Boda Z, Muszbek L, Bereczky Z.  
Founder effect is responsible for the p.Leu131Phe heparin-binding-site antithrombin mutation common in Hungary; phenotype analysis in a large cohort.  
J THROMB HAEMOST. 2016; 14 (4): 704-715 IF: 5.720 (2014. évi)
6. Péntes K, Vézina C, Bereczky Z, Katona É, Kun M, Muszbek L, Rivard GE  
Alloantibody developed in a factor XIII A subunit deficient patient during substitution therapy; characterization of the antibody  
HAEMOPHILIA 2016; 22 (2): 268-275 IF: 2.603 (2014. évi)
7. Kovac M, Mitic G, Mikovic Z, Mandic V, Djordjevic V, Muszbek L, Bereczky Z  
Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency  
THROMBOSIS RESEARCH 2016; 139: 111-113 IF: 2.447 (2014. évi)

**2015 (10 db cikk, IF: 25.539)**

1. Árokszallási A, Kerényi A, Katona É, Bereczky Z, Muszbek L, Boda Z, Schlammdinger Á  
The use of recombinant factor XIII in a major bleeding episode of a patient with congenital factor XIII deficiency – the first experience  
HAEMOPHILIA 2015; 21: e118-e121 IF: 2.603 (2014. évi)

2. Mezei ZA, Berezky Z, Katona É, Gindele R, Balogh E, Fiatal S, Balogh L, Czuriga I, Ádány R, Édes I, Muszbek L  
Factor XIII B subunit polymorphisms and the risk of coronary artery disease  
INT J MOL SCI 2015; 16: 1143-1159 IF: 2.862 (2014. évi)
3. Gebhart J, Laczkovics C, Posch F, Ay C, Reitter-Pfoertner SE, Haslacher H, Muszbek L, Wolberg AS, Pabinger I  
Plasma clot properties in patients with a mild-to-moderate bleeding tendency of unknown cause  
ANNALS OF HEMATOLOGY 2015; 94: 1301-1310 IF: 2.634 (2014. évi)
4. Kovács KB, Pataki I, Bárdos H, Fekete A, Pfliegler G, Haramura G, Gindele R, Komáromi I, Balla G, Ádány R, Muszbek L, Berezky Z  
Molecular characterization of p.Asp77Gly and the novel p.Ala163Val and p.Ala163Glu mutations causing protein C deficiency  
THROMBOSIS RESEARCH 2015; 135: 718-726 IF: 2.447 (2014. évi)
5. Bagoly Z  
Cancer and thrombosis: a fresh look at an old story  
THROMBOSIS RESEARCH 2015; 136: 1-2 IF: 2.447 (2014. évi)
6. Szaloki N, Krieger JW, Komaromi I, Toth K, Vamosi G  
Evidence for Homodimerization of the c-Fos Transcription Factor in Live Cells Revealed by Fluorescence Microscopy and Computer Modeling.  
MOLECULAR AND CELLULAR BIOLOGY 2015; 35 (21): 3785-3798 IF: 4.777 (2014. évi)
7. Toth L, Fekete A, Balogh G, Berezky Z, Komaromi I  
Dynamic properties of the native free antithrombin from molecular dynamics simulations: computational evidence for solvent- exposed Arg393 side chain  
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS 2015; 33 (9): 2023-2036 IF: 2.919 (2014. évi)
8. Berezki I, Mandi A, Roth E, Borbas A, Fizil A, Komaromi I, Sipos A, Kurtan T, Batta G, Ostorhazi E, Rozgonyi F, Vanderlinden E, Naesens L, Sztaricskai F, Herczegh P  
A few atoms make the difference: Synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives  
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2015; 94: 73-86 IF: 3.447 (2014. évi)
9. Ilonczai P, Oláh Z, Selmeczi A, Kerényi A, Berezky Z, Póka R, Schlamadinger Á, Boda Z  
Management and outcome of pregnancies in women with antithrombin deficiency: A single-center experience and review of literature  
BLOOD COAGULATION AND FIBRINOLYSIS 2015; 26 (7): 798-804 IF: 1.403 (2014. évi)
10. Berezky Zsuzsanna  
A véralvadás genetikai eredetű zavarai  
In: Oláh Éva (szerk.) Klinikai genetika: egyetemi tankönyv (ISBN: 978 963 226 540 7)  
Budapest: Medicina Könyvkiadó Zrt., 2015. pp. 487-500 IF: -

**2014 (10 db cikk, IF: 26.133)**

1. Katona E, Muszbek L, Devreese K, Kovács KB, Bereczky Z, Jonkers M, Shemirani AH, Mondelaers V, Ermens AAM  
Factor XIII deficiency: complete phenotypic characterization of two cases with novel causative mutations  
HAEMOPHILIA 2014; 20 (1): 114-20 IF: 2.603
2. Katona E, Péntes K, Csapó A, Fazakas F, Udvardy ML, Bagoly Z, Orosz ZZ, Muszbek L  
Interaction of factor XIII subunits  
BLOOD 2014; 123 (11): 1757-63 IF: 10.452
3. Kovac M, Mitic G, Miljic P, Mikovic Z, Mandic V, Djordjevic V, Radojkovic D, Bereczky Z, Muszbek L  
Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency  
THROMBOSIS RESEARCH 2014; 133 (6): 1158-60 IF: 2.447
4. Kovács EG, Katona E, Bereczky Z, Homoródi N, Balogh L, Tóth E, Péterfy H, Kiss RG, Édes I, Muszbek L  
Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods  
THROMBOSIS RESEARCH 2014; 133 (5): 811-6 IF: 2.447
5. Benyo M, Harsfalvi J, Pfliegler G, Molnar Z, Muranyi M, Jozsa T, Flasko T  
Present Practice of Thrombosis Prophylaxis of Radical Prostatectomy in a European Country: A Hungarian Multicenter Study  
UROLOGIA INT 2014; 92 (3): 289-93 IF: 1.426
6. Kovács B, Bereczky Z, Selmeczi A, Gindele R, Oláh Z, Kerényi A, Boda Z, Muszbek L  
Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies  
CLINICAL CHEMISTRY AND LABORATORY MEDICINE 2014; 52 (12): 1797-1806 IF: 2.707
7. Shemirani AH, Antalfi B, Pongrácz E, Mezei ZA, Bereczky Z, Csiki Z  
Factor XIII-A subunit Val34Leu polymorphism in fatal atherothrombotic ischemic stroke  
BLOOD COAG FIBRINOL 2014; 25 (4): 364-8 IF: 1.403
8. Németh I, Kiss-Szikszai A, Gulácsi K, Mándi A, Komáromi I, Kurtán T, Antus S  
Oxidation of enol acetate of flavanone with thallium (III) nitrate or phenyliodonium diacetate: a convenient new route to isoflavone and flavone  
MONATSH CHEM 2014; 145: 849-5 IF: 1.222
9. Benyo M, Harsfalvi J, Pfliegler G, Molnar Z, Muranyi M, Jozsa T, Flasko T  
Present practice of thrombosis prophylaxis of radical prostatectomy in a European country: a Hungarian multicenter study  
UROLOGIA INTERNAT 2014; 92 (3): 289-93 IF: 1.426

10. Benyo M, Harsfalvi J, Pfliegler G, Kiss Z, Murányi M, Berczi C, Varga A, Flasko T  
Trombózis profilaxis gyakorlat a magyar urológiai osztályokon  
MAGYAR UROLÓGIA 2014; 26 (1): 11-7 IF: -

**2013 (18 db cikk, IF: 41.873)**

1. Zsóri SK, Muszbek L, Csiki Z, Shemirani AH  
Validation of reference genes for the determination of platelet transcript level in healthy individuals and in patients with the history of myocardial infarction  
INT J MOL SCI 2013; 14 (2): 3456-66 IF: 2.339

2. Tóth L, Muszbek L, Komáromi I  
Mechanism of the irreversible inhibition of human cyclooxygenase-1 by aspirin as predicted by QM/MM calculations  
J MOL GRAPH MODEL 2013; 40: 99-109 IF: 2.022

3. Kovács EG, Katona E, Bereczky Z, Homoródi N, Balogh L, Tóth E, Péterfy H, Kiss RG, Édes I, Muszbek L  
New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals  
THROMB RES 2013; 131 (4): 320-4 IF: 2.427

4. Bereczky Zsuzsanna, Fialat Szilvia, Muszbek László  
Szív- és érrendszeri betegségek  
In: Ádány R, Sándor J, Brand A (szerk.)  
Népegészségügyi genomika (ISBN: 978 963 226 3885)  
Budapest: Medicina, 2013, pp. 121-43. IF: -

5. Bagoly Z, Sarkady F, Magyar T, Kappelmayer J, Pongracz E, Csiba L, Muszbek L  
Comparison of a new P2Y<sub>12</sub> receptor specific platelet aggregation test with other laboratory methods in stroke patients on Clopidogrel monotherapy  
PLoS ONE 2013; 8 (7): e69417 IF: 3.534

6. Lahav J, Tsvito A, Bagoly Z, Dardik R, Inbal A  
Factor XIII improves platelet adhesion to fibrinogen by protein disulfide isomerase-mediated activity  
THROMB RES 2013; 131 (4): 338-41 IF: 2.427

7. Zsóri KS, Csiki Z, Katona É, Bereczky Z, Shemirani AH  
Vitamin B<sub>12</sub> level in peripheral arterial disease  
J THROMB THROMBOLYS 2013; 36 (1): 77-83. IF: 2.039

8. Losonczy G, Fazakas F, Pfliegler G, Komáromi I, Balazs E, Penzes K, Berta A  
Three novel germ-line VHL mutations in Hungarian von Hippel-Lindau patients, including a nonsense mutation in a fifteen-year-old boy with renal cell carcinoma  
BMC MED GENET 2013; 14: 3 IF: 2.450

9. Kiss A, Becsi B, Kolozsvári B, Komáromi I, Kover KE, Erdodi F  
Epigallocatechin-3-gallate and penta-O-galloyl-beta-D-glucose inhibit protein phosphatase-1.  
FEBS J 2013; 280 (2): 612-26 IF: 3.341
10. Antalfi B, Pongrácz E, Csiki Z, Mezei ZA, Shemirani AH  
Factor XIII-A subunit Val34Leu polymorphism in fatal hemorrhagic stroke  
INT J LAB HEMATOL 2013; 35 (1): 88-91 IF: 1.870
11. Takáts AT, Shemirani AH, Zsóri KS, András C, Csiki Z  
Association of von Willebrand factor and fibrinogen plasma levels with primary Raynaud's  
phenomenon in male and female patients  
RHEUMATOL INT 2013; 33 (4): 1083-4 IF: 1.627
12. Mitchell JA Nagymihály R, Uhrinyi ON, Harsfalvi J  
Measurement of Thrombin in Different Matrices: Whole Blood, Platelet-Rich and Platelet-Poor  
Plasma Using Fluorogenic Substrate ZGGR-AMC.  
ACTA HAEMATOLOGICA 2013; 130 (3): 150-2 IF: 0.994
13. Kovács B, Bereczky Z, Oláh Z, Gindele R, Kerényi A, Selmeczi A, Boda Z, Muszbek L  
The superiority of anti-FXa assay over anti-FIIa assay in detecting heparin-binding site  
antithrombin deficiency  
AM J CLIN PATHOL 2013; 140 (5): 675-9 IF: 4.602
14. Bokor É, Fekete A, Varga G, Szöcs B, Czifrák K, Komáromi I, Somsák L.  
C-( $\beta$ -D-Glucopyranosyl)formamidrazones, formic acid hydrazides and their transformations into  
3-( $\beta$ -D-glucopyranosyl)-5 substituted-1,2,4-triazoles: a synthetic and computational study  
TETRAHEDRON 2013; 69 (48): 10391-404 IF: 2.772
15. Hegyi B, Komáromi I, Nánási PP, Szentandrassy N  
Selectivity problems with drugs acting on cardiac  $\text{Na}^+$  and  $\text{Ca}^{2+}$  channels  
CURR MED CHEM 2013; 20 (20): 2552-71 IF: 3.715
16. Hegyi B, Komáromi I, Kistamás K, Ruzsnavszky F, Váczi K, Horváth B, Magyar J, Bányász  
T, Nánási PP, Szentandrassy N  
Tetrodotoxin blockade on canine cardiac L-type  $\text{Ca}^{2+}$  channels depends on pH and redox potential  
MARINE DRUGS 2013; 11 (6): 2140-53 IF: 4.334
17. Szomjak E, Csiki Z, Zsori KS, Andras C, Shemirani AH  
The effect of FXIII-A Val34Leu genotype on the risk of peripheral arterial disease  
BLOOD COAG FIBRINOL 2013; 24 (3): 351-2 IF: 1.380
18. Szaloki M, Vitalyos G, Harsfalvi J, Hegedus C  
Binding of leachable components of polymethyl methacrylate (PMMA) and peptide on modified  
SPR chip  
IOP CONF SER: MATER SCI ENG 2013; 47: 1-6 IF: -

**2012 (21 db cikk, IF: 59.734)**

1. Simon A, Bagoly Z, Hevessy Z, Csathy L, Katona E, Vereb Gy, Ujfalusi A, Szerafin L, Muszbek L, Kappelmayer J  
Expression of coagulation factor XIII subunit A in acute promyelocytic leukemia  
CYTOM PART B-CLIN CY 2012; 82 (4): 209-16 IF: 2.231
2. Koncz Z, Bagoly Z, Haramura G, Mezei ZA, Muszbek L  
Thrombomodulin-dependent effect of factor V<sub>Leiden</sub> mutation on factor XIII activation.  
THROMB RES 2012; 129 (4): 508-13 IF: 3.133
3. Koncz Z, Bagoly Z, Haramura G, Mezei ZA, Muszbek L  
Thrombomodulin-dependent effect of factor v Leiden mutation on the cross-linking of  $\alpha$  2-plasmin inhibitor to fibrin and its consequences on fibrinolysis  
THROMB RES 2012; 130 (3): 528-34 IF: 3.133
4. Katona E, Penzes K, Molnar E, Muszbek L  
Measurement of factor XIII activity in plasma  
CLIN CHEM LAB MED 2012; 50 (7): 1191-202 IF: 3.009
5. Balogh E, Bereczky Z, Katona E, Koszegi Z, Edes I, Muszbek L, Czuriga I  
Interaction between homocysteine and lipoprotein(a) increases the prevalence of coronary artery disease/myocardial infarction in women: A case-control study.  
THROMB RES 2012; 129 (2): 133-8 IF: 3.133
6. Bagoly Z, Koncz Z, Harsfalvi J, Muszbek L  
Factor XIII, clot structure, thrombosis.  
THROMB RES 2012; 129 (3): 382-7 IF: 3.133
7. Bagoly Z, Katona E, Muszbek L  
Factor XIII and inflammatory cells  
THROMB RES 2012; 129 (S2): S77-S81 IF: 3.133
8. Szilágyi S, Péter A, Magyar TM, Balogh S, Bereczky Z  
Recurrent arterial thrombosis associated with the antithrombin basel variant and elevated lipoprotein(a) plasma level in an adolescent patient  
J PEDIAT HEMATOL ONC 2012; 34 (4): 276-9 IF: 0.973
9. Herczeg M, Lazar L, Bereczky Z, Kover KE, Timari I, Kappelmayer J, Liptak A, Antus S, Borbas A  
Synthesis and anticoagulant activity of bioisosteric sulfonic-acid analogues of the antithrombin-binding pentasaccharide domain of heparin  
CHEM-EUR J 2012; 18 (34): 10643-52 IF: 5.831
10. Árokszállási A, Ilonczai P, Rázsó K, Oláh Z, Bereczky Z, Boda Z, Schlammdinger A  
Acquired haemophilia: An often overlooked cause of bleeding - Experience from a Hungarian tertiary care centre  
BLOOD COAGUL FIBRIN 2012; 23 (7): 584-9 IF: 1.248

11. Somogyi Á, Smith M A, Vuitton V, Thissen R, Komáromi I  
Chemical ionization in the atmosphere? A model study on negatively charged "exotic" ions generated from Titan's tholins by ultrahigh resolution MS and MS/MS  
INT J MASS SPECTROM 2012; 316-318: 157-63 IF: 2.142
12. Owen MC, Csizmadia IG, Jojárt B, Viskolcz B, Tóth L, Komáromi I,  
The effect of newly developed OPLS-AA alanyl radical parameters on peptide secondary structure  
J CHEM THEORY COMPUT 2012; 8 (8): 2569-80 IF: 5.389
13. Németh I, Kiss-Szikszai A, Illyés TZ, Mándi A, Komáromi I, Kurtán T, Antus S  
Oxidative rearrangement of flavanones with thallium(III) nitrate, lead tetraacetate and hypervalent iodines in trimethyl orthoformate and perchloric or sulfuric acid  
Z NATURFORSCH B 2012; 67b: 1289-96 IF: 0.899
14. Hegyi B, Barandi L, Komaromi I, Papp F, Horvath B, Magyar J, Banyasz T, Krasznai Z, Szentandrassy N, Nanasi PP  
Tetrodotoxin blocks L-type Ca<sup>2+</sup> channels in canine ventricular cardiomyocytes  
PFLUG ARCH EUR J PHYS 2012; 464 (2): 167-74 IF: 4.866
15. Takáts AT, Shemirani AH, Zsóri KS, András C, Csiki Z  
Prothrombotic polymorphism in patients with Raynaud's phenomenon and migraine  
ACTA PHYSIOL HUNG 2012; 99 (4): 430-5 IF: 0.882
16. Mendelboum RS, Szekeres-Csiki K, Jenei A, Nagy J, Shenkman B, Savion N, Hársfalvi J  
Coating conditions matter to collagen matrix formation regarding von Willebrand factor and platelet binding: Collagen matrix matters to VWF and platelet binding  
THROMBOSIS RESEARCH 2012; 129 (6): e29-e35 IF: 3.133
17. Shemirani AH, Nagy B, Takáts AT, Zsóri KS, András C, Kappelmayer J, Csiki Z  
Increased mean platelet volume in primary Raynaud's phenomenon  
PLATELETS 2012; 23 (4): 312-6 IF: 2.240
18. Andras C, Tóth L, Molnár C, Tanyi M, Csiki Z, Dezső B, Pósn J, Shemirani AH, Csiki E, Szántó J  
Correlations between clinicopathological parameters and molecular signatures of primary tumors for patients with stage T3N0 colorectal adenocarcinomas: a single center retrospective study on 100 cases  
HEPATO-GASTROENTEROL 2012; 59 (116): 1091-7 IF: 0.774
19. Papp M, Vitalis Z, Altörjay I, Tornai I, Udvardy M, Harsfalvi J, Vida A, Kappelmayer J, Lakatos PL, Antal-Szalmas P  
Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections  
LIVER INT 2012; 32 (4): 603-11 IF: 3.870

20. Darago A, Fagyas M, Siket IM, Facsko A, Megyesi Z, Kalasz J, Galajda Z, Szerafin T, Harsfalvi J, Edes I, Papp Z, Toth A, Szentmiklosi J  
Differences in angiotensin convertase enzyme (ACE) activity and expression may contribute to shorter event free period after coronary artery bypass graft surgery.  
CARDIOVASC THER 2012; 30 (3): 136-44 IF: 2.852

21. Benyo M, Flasko T, Molnar Z, Kerenyi A, Batta Z, Jozsa T, Harsfalvi J  
Follow-up of thrombin generation after prostate cancer surgery: global test for increased hypercoagulability  
PLOS ONE 2012; 7 (12): e51299 IF: 3.730

**2011 (19 db cikk, IF: 111.74)**

1. Orosz ZZ, Katona E, Facsko A, Modis L, Muszbek L, Berta A  
Factor XIII subunits in human tears; their highly elevated levels following penetrating keratoplasty  
CLIN CHIM ACTA 2011; 412 (3-4): 271-6 IF: 2.535

2. Muszbek L, Bagoly Z, Cairo A, Peyvandi F  
Novel aspects of factor XIII deficiency.  
CURR OPIN HEMATOL 2011; 18 (5): 366-72 IF: 4.520

3. Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E  
Factor XIII: a coagulation factor with multiple plasmatic and cellular functions  
PHYSIOL REV 2011; 91 (3): 931-72 IF: 26.866

4. Bereczky Zs, Muszbek L (szerk.)  
A klinikai kutatások tervezése és kivitelezése: elméleti és módszertani alapok  
Budapest: Medicina, 2011 IF: -

Fejezetek:

*Bereczky Z: A klinikai kutatás tárgya, szerepe az orvostudományban, történeti áttekintés, pp: 9-14.*

*Bereczky Z: A helyes tudományos kérdésfelvetés, hipotézisalkotás, pp:15-22*

*Muszbek L: A klinikai tanulmányok típusai és jellegzetességei; deskriptív és analitikus obszervációs tanulmányok, pp. 23-36.*

*Muszbek L, Bereczky Zs: A megfigyelésen alapuló (obszervációs) tanulmányok és közlésük javítására irányuló törekvések, pp. 37-44.*

*Bereczky Z: Az obszervációs klinikai tanulmányok résztvevőinek kiválasztása, a résztvevők számának meghatározása, pp 65-75*

*Hársfalvi J: A klinikai tanulmányok minőségirányítása és ellenőrzése, pp.77-88*

*Bereczky Z: A klinikai tanulmányok megtervezése, protokollírás, költségtervezés, pp. 89-98*

*Fazakas F: Az adatbázisok használata a klinikai kutatásban, pp 99-112*

*Bagoly Z: A klinikai kutatások előfeltételeinek biztosítása, pp.113-126*

*Bagoly Z: Kérdőívek megtervezése, interjúk, pp.129-138*

*Bagoly Z: Intézményen kívüli, multicentrikus és nemzetközi klinikai tanulmányok, pp 139-148*

*Katona E: A klinikai kutatások etikai vonatkozásai, pp 161- 178*

*Udvardy ML: Klinikai kutatások a résztvevő vizsgálati alanyok szempontjából, pp. 195-202*

*Udvardy ML: A klinikai kutatásokkal összefüggő kockázatok, pp. 203-211*



5. Komáromi I, Bagoly Z, Muszbek L  
Factor XIII: novel structural and functional aspects  
J THROMB HAEMOST 2011; 9 (1): 9-20 IF: 5.731
6. Kohler HP, Ichinose A, Seitz R, Ariens RAS, Muszbek L  
Diagnosis and classification of factor XIII deficiencies.  
J THROMB HAEMOST 2011; 9 (7): 1404-1406 IF: 5.731
7. Bereczky Z, Muszbek L  
Factor XIII and venous thromboembolism  
SEMIN THROMB HEMOST 2011; 37 (3): 305-14 IF: 4.524
8. Kappelmayer J, Antal C, Bereczky Z  
Accessibility of special clinical laboratory tests in Hungary: [Speciális klinikai laboratóriumi vizsgálatok hazai elérhetősége]  
ORVOSI HETILAP 2011; 152 (51): 2056-62 IF: -
9. Szikra D, Mándi A, Borbás A, Nagy IP, Komáromi I, Kiss-Sziksza A, Herczeg M, Antus S  
A kinetic study on the reductive opening of the diphenylmethylen acetal in methyl 2,3-O-diphenylmethylen-alpha-L-rhamnopyranoside  
CARBOHYD RES 2011; 346 (13): 2004-6 IF: 2.332
10. Pintér G, Bereczki I, Ötvös R, Batta Gy, Kéki S, Mándi A, Komáromi I, Takács-Novák K, Sztaricskai F, Róth E, Ostorházi E, Rozgonyi F, Naesens L, Herczeg P  
Új, antibakteriális és influenzavírus-ellenes lipofil teikoplanin- és risztocetin-aglikonszármazékok szintézise  
MAGYAR KÉMIAI FOLYÓIRAT 2011; 117 (2-3): 51-5 IF: -
11. Mándi A, Komáromi I, Borbás A, Szikra D, Nagy IP, Lipták A, Antus S  
Quantum chemical studies on the partial hydrogenolysis of methyl 2,3-O-diphenylmethylen-alpha-L-rhamnopyranoside  
TETRAHEDRON LETT 2011; 52 (12): 1256-9 IF: 2.683
12. Herczeg M, Lázár L, Mándi A, Borbás A, Komáromi I, Lipták A, Antus S  
Synthesis of disaccharide fragments of the AT-III binding domain of heparin and their sulfonatomethyl analogues  
CARBOHYD RES 2011; 346 (13): 1827-36 IF: 2.332
13. Cai YS, Kurtán T, Miao ZH, Mándi A, Komáromi I, Liu HL, Ding J, Guo YW  
Palmarumycins BG1-BG7 and preussomerin BG1: establishment of their absolute configurations using theoretical calculations of electronic circular dichroism spectra  
J ORG CHEM 2011; 76 (6): 1821-30 IF: 4.450
14. Shemirani AH, Szomják E, Balogh E, András C, Kovács D, Ács J, Csiki Z  
Polymorphism of clotting factors in Hungarian patients with Raynaud's phenomenon  
BLOOD COAGUL FIBRIN 2011; 22 (1): 56-9 IF: 1.238

15. Csiki Z, Garai I, Shemirani AH, Papp G, Zsóri KS, András C, Zeher M  
The effect of metoprolol alone and combined metoprolol-felodipin on the digital microcirculation of patients with primary Raynaud's syndrome  
MICROVASC RES 2011; 82 (1): 84-7 IF: 2.828
16. Lakatos PL, Kiss LS, Palatka K, Altorjay I, Antal-Szalmás P, Palyu E, Udvardy M, Molnár T, Molnár T, Farkas K, Veres G, Harsfalvi J, Papp J, Papp M  
Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease  
INFLAMM BOWEL DIS 2011; 17 (3): 767-77 IF: 4.855
17. Mogyorósy G, Kovács T, Nagy A, Kerényi A, Szöllősi Z, Bereczky Zs, Kiss Cs  
Recurrent intraventricular thrombosis in a child with dilated cardiomyopathy and antithrombin deficiency  
CARDIOL HUNG 2011; 41 (1): 18-21 IF: -
18. Olah Z, Bereczky Z, Szarvas M, Boda Z  
Coagulation: Cascade!  
LANCET 2011; 378 (9792): 740 IF: 38.278
19. Vitalis Z, Altorjay I, Tornai I, Palatka K, Kacska S, Palyu E, Tornai D, Udvardy M, Harsfalvi J, Dinya T, Veres G, Lakatos PL, Papp M  
Phenotype polymorphism of haptoglobin: A novel risk factor for the development of infection in liver cirrhosis  
HUM IMMUNOL 2011; 72 (4): 348-54 IF: 2.837

**2010 (10 db cikk, IF: 32.815)**

1. Veres K, Szodoray P, Szekanecz Z, Lakos G, Kiss E, Laczik R, Sipka S, Bodolay E, Zeher M, Muszbek L, Szegedi G, Soltesz P  
Clinical and immunoserological characteristics of the transition from primary to overlap antiphospholipid syndrome.  
LUPUS 2010; 19 (13): 1520-6 IF: 2.600
2. Shemirani AH, Pongracz E, Antalfi B, Adany R, Muszbek L  
Factor XIII A subunit Val34Leu polymorphism in patients suffering atherothrombotic ischemic stroke  
THROMB RES 2010; 126 (2): 159-62 IF: 2.372
3. Orosz ZZ, Katona E, Facsko A, Berta A, Muszbek L  
A highly sensitive chemiluminescence immunoassay for the measurement of coagulation factor XIII subunits and their complex in tears  
J IMMUNOL METHODS 2010; 353 (1-2): 87-92 IF: 2.340
4. Muszbek L, Bereczky Z, Bagoly Z, Shemirani AH, Katona E  
Factor XIII and atherothrombotic diseases  
SEMIN THROMB HEMOST 2010; 36 (1): 18-33 IF: 4.169

5. Muszbek L, Bereczky Z, Kovács B, Komáromi I  
Antithrombin deficiency and its laboratory diagnosis  
CLIN CHEM LAB MED 2010; 48 (S1): S67-S78 IF: 2.069
6. Bereczky Z, Kovács KB, Muszbek L  
Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game  
CLIN CHEM LAB MED 2010; 48 (S1): S53-S66 IF: 2.069
7. Bagoly Z, Fazakas F, Marosi A, Torok O, Bereczky Z, Haramura G, Toth J, Kappelmayer J, Muszbek L  
Variant type Glanzmann thrombasthenia caused by homozygous p.742R>X mutation in beta3 integrin  
THROMB RES 2010; 125 (5): 427-31 IF: 2.372
8. Fejes Z, Mandi A, Komaromi I, Majoros L, Batta G, Herczegh P  
A synthetic and in silico study on the highly regioselective Diels-Alder reaction of the polyenic antifungal antibiotics natamycin and flavofungin  
TETRAHEDRON LETTERS 2010; 51 (38): 4968-71 IF: 2.618
9. Papp M, Lakatos PL, Harsfalvi J, Farkas G, Palatka K, Udvardy M, Molnar T, Farkas K, Nagy F, Veres G, Lakatos L, Kovacs A, Dinya T, Kocsis AK, Papp J, the Hungarian IBD Study Group, Altorjay I  
Mannose-binding lectin level and deficiency is not associated with inflammatory bowel diseases, disease phenotype, serology profile, and NOD2/CARD15 genotype in a large Hungarian cohort  
HUM IMMUNOL 2010; 71 (4): 407-13 IF: 2.872
10. Altorjay I, Vitalis Z, Tornai I, Palatka K, Kacska S, Farkas G, Udvardy M, Harsfalvi J, Dinya T, Orosz P, Lombay B Jr, Par G, Par A, Csak T, Osztoivits J, Szalay F, Csepregi A, Lakatos PL, Papp M  
Mannose-binding lectin deficiency confers risk for bacterial infections in a large Hungarian cohort of patients with liver cirrhosis.  
J HEPATOL 2010; 53 (3): 484-91 IF: 9.334

**2009 (17 db cikk, IF: 65.958)**

1. Szűcs G, Ajzner E, Muszbek L, Simon T, Szepesi K, Fülesdi B  
Assessment of thrombotic risk factors predisposing to thromboembolic complications in prosthetic orthopedic surgery.  
J ORTHOP SCI 2009; 14 (5): 489-90 IF: 1.027
2. Péntes K, Kövér KE, Fazakas F, Haramura G, Muszbek L  
Molecular mechanism of the interaction between activated factor XIII and its glutamine donor peptide substrate  
J THROMB HAEMOST 2009; 7 (4): 627-33 IF: 6.069
3. Nagy B jr., Simon Z, Bagoly Z, Muszbek L, Kappelmayer J  
Binding of plasma factor XIII to thrombin-receptor activated human platelets  
THROMB HAEMOSTASIS 2009; 102 (1): 83-9 IF: 4.451

4. Kovács KB, Tisza B, Komáromi I, Muszbek L, Berczky Z  
 Inherited Factor V deficiency associated with a novel heterozygous missense mutation (p.G493R) in a patient with excessive surgical bleeding  
 THROMB HAEMOSTASIS 2009; 102 (4): 787-9 IF: 4.451
5. Karimi M, Berczky Z, Cohan N, Muszbek L  
 Factor XIII deficiency  
 SEMIN THROMB HEMOST 2009; 35 (4): 426-38 IF: 3.214
6. Ajzner É, Schlammadinger Á, Kerényi A, Berczky Z, Katona É, Haramura G, Boda Z, Muszbek L  
 Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency  
 BLOOD 2009; 113 (3): 723-5 IF: 10.555
7. Lahav J, Karniel E, Bagoly Z, Sheptovitsky V, Dardik R, Inbal A  
 Coagulation factor XIII serves as protein disulfide isomerase  
 THROMB HAEMOSTASIS 2009; 101 (5): 840-4 IF: 4.451
8. Pintér G, Batta GY, Kéki S, Mándi A, Komáromi I, Takács-Novák K, Sztaricskai F, Róth E, Ostorházi E, Rozgonyi F, Naesens L, Herczegh P  
 Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study  
 J MED CHEM 2009; 52 (19): 6053-61 IF: 4.802
9. Jakab Z, Mándi A, Borbás A, Bényei A, Komáromi I, Lázár L, Antus S, Lipták A  
 Synthesis, regioselective hydrogenolysis, partial hydrogenation, and conformational study of dioxane and dioxolane-type (9'-anthracenyl)methylene acetals of sugars  
 CARBOHYD RES 2009; 344 (18): 2444-53 IF: 2.025
10. Fejes Z, Mándi A, Komáromi I, Bényei A, Naesens L, Fenyvesi F, Szilágyi L, Herczegh P  
 Synthesis of a pericosine analogue with a bicyclo[2.2.2]octene skeleton  
 TETRAHEDRON 2009; 65 (39): 8171-5 IF: 3.219
11. Udvardy ML, Szekeres-Csiki K, Hársfalvi J  
 Novel evaluation method for densitometric curves of von Willebrand factor multimers and a new parameter (M(MW)) to describe the degree of multimersation  
 THROMB HAEMOSTASIS 2009; 102 (2): 412-7 IF: 4.451
12. Toth J, Kappelmayer J, Udvardy ML, Szanto T, Szarvas M, Rejto L, Soltesz P, Udvardy M, Hársfalvi J  
 Increased platelet glycoprotein Ib receptor number, enhanced platelet adhesion and severe cerebral ischaemia in a patient with polycythaemia vera  
 PLATELETS 2009; 20 (4): 282-7 IF: 2.272

13. Szántó T, Vanhoorelbeke K, Tóth G, Vandebulcke A, Tóth J, Noppe W, Deckmyn H, Hársfalvi J  
Identification of a VWF peptide antagonist that blocks platelet adhesion under high shear conditions by selectively inhibiting the VWF-collagen interaction.  
J THROMB HAEMOST 2009; 7 (10): 1680-7 IF: 6.069
14. Molvarec A, Rigo J Jr, Boze T, Derzsy Z, Cervenak L, Mako V, Gombos T, Udvardy ML, Hársfalvi J, Prohaszka Z  
Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.  
THROMB HAEMOSTASIS 2009; 101 (2): 305-11 IF: 4.451
15. Gombos T, Mako V, Cervenak L, Papassotiriou J, Kunde J, Hársfalvi J, Forhecz Z, Pozsonyi Z, Borgulya G, Janoskuti L, Prohászka Z  
Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure  
THROMB HAEMOSTASIS 2009; 102 (3): 573-80 IF: 4.451
16. Pfliegler G, Blasko G, Boda Z, Csiba L, David M, Kiss RG, Losonczy H, Udvardy M, Ajzner E, Altorjay I, Bereczki Z, Czuriga I, Fonay K, Fulesdi B, Kiss A, Matyus J, Molnar C, Nemeth J, Papai Z, Preda I, Rudas L, Sas G, Szendroi M, Szekely H, Vezendi K, Kemeny L, Acsady G, Verebely T, Hajnal F, Merkely B, Vecsei L, Hangody L, Palko A, Pavlik G, Thurzo L, Kolozsvari L, Tenke P  
A thromboembolia kockázatának csökkentése és kezelése  
ORVOSI HETILAP 2009; 150 (52): 2335-403 IF: -
17. Szűcs G, Muszbek L, Ajzner E, Simon T, Szepesi K, Fulesdi B  
A tromboembóliás szövődményekre hajlamosító tényezők vizsgálata ortopédiai protézis beültetések esetén  
ANESZTEZIOL INTENZÍV TER 2009; 39 (1): 17-23 IF: -